Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SHPH | 8-K | bearish | 6/10 | Shuttle Pharmaceuticals dismissed its auditor, Forvis Mazars, effective after the Q3 2026 10-Q filing. The dismissal fol | Oct 22, 2026 |
| KNSA | 8-K | neutral | 2/10 | Kiniksa appointed Ross Moat as President and COO, effective immediately, with a base salary increase to $700,000 and tar | Oct 22, 2026 |
| AARD | 8-K | bullish | 7/10 | Aardvark Therapeutics announced that the FDA has lifted the clinical hold on its IND for ARD-101 for hyperphagia in Prad | Oct 22, 2026 |
| AZTR | 8-K | neutral | 3/10 | Azitra, Inc. filed a certificate of amendment to effect a 1-for-10 reverse stock split, effective October 26, 2026. The | Oct 22, 2026 |
| KPTI | 8-K | bearish | 6/10 | Karyopharm Therapeutics filed an 8-K extending its forbearance period under a Forbearance Agreement and Limited Waiver t | Oct 22, 2026 |
| GYRE | 8-K | neutral | 2/10 | Gyre Therapeutics entered into formal employment agreements with CEO Ying Luo and CFO Thomas Eastling on October 16, 202 | Oct 22, 2026 |
| MBX | 8-K | neutral | 2/10 | MBX Biosciences appointed Peter Radovich as an independent Class I director, effective October 20, 2026, expanding the b | Oct 22, 2026 |
| MIRA | 8-K | bullish | 5/10 | MIRA Pharmaceuticals reported positive preclinical results for MIRA-55, an oral synthetic cannabinoid analog for chronic | Oct 22, 2026 |
| ABUS | 8-K | bullish | 6/10 | Arbutus Biopharma announced that the FDA has lifted the clinical hold on the IND for AB-101, its oral PD-L1 inhibitor fo | Oct 22, 2026 |
| LNTH | 8-K | neutral | 5/10 | Lantheus disclosed that it and acquirer Curium US Holdings each received a Second Request from the FTC on October 21, 20 | Oct 22, 2026 |
| SGMT | 8-K | neutral | 4/10 | Sagimet Biosciences filed an 8-K with an updated investor presentation on October 22, 2026. The presentation highlights | Oct 22, 2026 |
| KRRO | 8-K | bullish | 6/10 | Korro Bio reported preclinical data for KRRO-111, its RNA-editing candidate for Alpha-1 Antitrypsin Deficiency (AATD), s | Oct 22, 2026 |
| UTHR | 8-K | neutral | 4/10 | United Therapeutics announced a $2.0 billion share repurchase authorization, effective through October 21, 2027. The com | Oct 22, 2026 |
| BHVN | 8-K | bullish | 6/10 | Biohaven announced that the FDA accepted for review its resubmitted NDA for troriluzole (Vyglxia) in spinocerebellar ata | Oct 22, 2026 |
| CGTX | 8-K | bullish | 7/10 | Cognition Therapeutics announced FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine (CT1812) in dem | Oct 22, 2026 |
| SUPN | 8-K | bullish | 6/10 | Supernus announced the FDA recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for advanced P | Oct 21, 2026 |
| ELOX | 8-K | neutral | 4/10 | Eloxx Pharmaceuticals appointed Geno J. Germano to its board (expanding from five to six directors) and announced the fi | Oct 21, 2026 |
| TKNO | 8-K | mixed | 6/10 | Alpha Teknova priced a $40M underwritten public offering of 8M shares at $5.00/share (closing Oct 22), concurrently disc | Oct 21, 2026 |
| TCRT | 8-K | bullish | 7/10 | Alaunos Therapeutics filed this 8-K to report that, following its October 13, 2026 acquisition of Velaris Therapeutics a | Oct 21, 2026 |
| MEDP | 8-K | bullish | 6/10 | Medpace reported Q3 2026 revenue of $716.0M (+8.5% YoY) and GAAP diluted EPS of $4.84, slightly below consensus estimate | Oct 21, 2026 |
| IONS | 8-K | bullish | 7/10 | Ionis Pharmaceuticals' partner GSK announced FDA approval of HIBSAGO (bepirovirsen) for chronic hepatitis B, a first-in- | Oct 21, 2026 |
| RCUS | 8-K | neutral | 4/10 | Arcus Biosciences disclosed a preliminary Q3 2026 cash balance of ~$694M, down from $876M at Q2 end and $1.01B at year-e | Oct 21, 2026 |
| IRD | 8-K | neutral | 2/10 | Opus Genetics announced the transition of Chief Scientific and Development Officer Ashwath Jayagopal, effective October | Oct 21, 2026 |
| ABT | 8-K | bullish | 6/10 | Abbott announced its intention to spin off its global Nutrition business (~$8.5B annual sales) into an independent publi | Oct 21, 2026 |
| INMB | 8-K | bullish | 7/10 | INmune Bio filed an 8-K announcing two key Ebstrocel (CORDStrom) milestones: submission of a pre-MAA package to the UK M | Oct 21, 2026 |
| IMNN | 8-K | neutral | 4/10 | Imunon entered into an asset purchase agreement to sell its ThermoDox program to VoxelDox Therapeutics. The deal is cont | Oct 21, 2026 |
| VYGR | 8-K | neutral | 3/10 | Voyager Therapeutics promoted Robin Swartz from COO/CBO to President, effective October 20, 2026, with a plan for her to | Oct 21, 2026 |
| ABT | 8-K | bearish | 6/10 | Abbott reported Q3 2026 adjusted diluted EPS of $1.42, missing consensus of $1.64 by 13.4%, and revenue of $13.013B vs $ | Oct 21, 2026 |
| ROIV | 8-K | bullish | 7/10 | Roivant and its subsidiary Priovant announced positive Phase 3 results for brepocitinib in non-infectious uveitis (NIU). | Oct 21, 2026 |
| GNPX | 8-K | neutral | 2/10 | Genprex issued a press release highlighting peer-reviewed mouse research on the TUSC2 tumor suppressor gene's role in br | Oct 21, 2026 |